Abstract: Provided herein are pharmaceutical compositions comprising a therapeutically effective amount of lipoic acid choline ester or derivatives thereof and a non-aqueous excipient mixed in an aqueous solution. Also provided herein are non-aqueous compositions prepared by mixing the therapeutically effective amount of lipoic acid choline ester and the non-aqueous excipient. The non-aqueous compositions can be further mixed with the aqueous solution.

Abstract: The present disclosure provides compositions comprising ephedrine sulfate ready for immediate use in a clinical setting, and methods of making and using same.

Abstract: The present invention refers to the use of sodium channel blockers such as tetrodotoxin or saxitoxin, its analogues/derivatives as well as their acceptable salts, for the production of a medicament for the treatment of neuropathic pain resulting from chemotherapy.

Abstract: Rinse aids and sanitizing rinse aids for various applications, including institutional machine sanitizing are disclosed. In particular, concentrated and use compositions, such as concentrated liquid rinse aid compositions, employing a synergistic combination of a quaternary ammonium compound and anionic surfactant are disclosed. In particular, the present invention provides compositions and methods of a sanitizing rinse providing desired antimicrobial efficacy against a broad spectrum of gram negative microbes, suitable foaming profiles, and beneficial applications of use of the same, including low temperature sanitizing rinse are provided.

Abstract: The present invention relates to the treatment of osteoarthritis with certain gamma-aminobutyric acid derivatives. Patients to be treated include those having elevated pain sensitivity. Specific therapies disclosed include those in which the gam-ma-aminobutyricacid derivative is administered as a single active agent rather than in combination with another active agent.

Abstract: Methods of improving neurodegenerative disease with CCR3 modulating agents are provided. The methods include administering a therapeutically effective amount of the CCR3 modulating agent to the subject, with a concomitant improvement in cognition, motor, or other neurodegenerative-affected function. Cognitive and motor diseases upon which the methods of the invention can improve cognition include Alzheimer's disease, Parkinson's disease, frontotemporal dementia, Huntington's disease, amyotrophic lateral sclerosis, multiple sclerosis, glaucoma, myotonic dystrophy, vascular dementia, progressive supranuclear palsy.

Abstract: A method and medicament comprising 4,4,4-trifluoro-N-[(1S)-2-[[(7S)-5-(2-hydroxyethyl)-6-oxo-7H-pyrido[2,3-d][3]benzazepin-7-yl]amino]-1-methyl-2-oxo-ethyl]butanamide or a pharmaceutically acceptable salt or hydrate thereof for treating aggressive peripheral T-cell lymphoma is provided.

Abstract: The present invention is directed to a method for improving the occlusiveness of a topical pharmaceutical or cosmetic formulation in use in a patient in need thereof, comprising adding to the formulation at least 0.1- to about 10% w/w of one or more of a monofatty acid ester of glycerin and/or one or more of a monofatty acid ester of glycol, or mixtures thereof. The present invention is also directed to a method for maintaining skin barrier efficiency of the stratum corneum of a patient in need thereof, comprising applying to the skin of said patient a pharmaceutical or cosmetic formulation containing at least 3% w/w of one or more of a monofatty acid ester of glycerin and/or one or more of a monofatty acid ester of glycol, or mixtures thereof.

Abstract: The use of tapentadol for the manufacture of a medicament comprising at least one administration unit A containing dose a of tapentadol and at least one administration unit B containing dose b of tapentadol, where dose a<dose b, for the treatment of pain.

Abstract: Compounds and compositions are provided that comprise selective b-glucuronidase inhibitors. The compounds and compositions can ameliorate the side effects of chemotherapeutic agents and can improve the efficacy of such agents, including irinotecan and non-steroidal anti-inflammatory drugs.

Abstract: Aspects of the present invention are directed to a method for improving the occlusiveness of a topical pharmaceutical or cosmetic formulation in use in a patient in need thereof, comprising adding to the formulation at least 0.1-to about 10% w/w of one or more of a monofatty acid ester of glycerin and/or one or more of a monofatty acid ester of glycol, or mixtures thereof. Aspects of the present invention are also directed to a method for maintaining skin barrier efficiency of the stratum corneum of a patient in need thereof, comprising applying to the skin of said patient a pharmaceutical or cosmetic formulation containing at least 3% w/w of one or more of a monofatty acid ester of glycerin and/or one or more of a monofatty acid ester of glycol, or mixtures thereof.

Abstract: This disclosure relates to a composition for the prevention or the treatment of inflammatory skin diseases or severe pruritus comprising an aqueous solubilized ursodeoxycholic acid (UDCA). According to this disclosure, inflammatory skin diseases and severe pruritus such as atopic dermatosis, acne, psoriasis, hives, inflammatory skin disease, seborrheic dermatitis and contact dermatitis can be effectively alleviated or treated. Therefore, the composition comprising aqueous solubilized ursodeoxycholic acid of this disclosure can be best used as a pharmaceutical, food or cosmetic composition, and can be used particularly as an external preparation to exhibit its effect.

Abstract: The present invention relates to the use of carotenoids, in particular a microbial carotenoid compound of formula I, such as methyl-glycosyl-apo-8?-lycopenoate or glycosyl-apo-8?-lycopene, for restoring and/or maintaining a health-beneficial gut microbial composition in a subject. The invention further provides the use of said compound in the treatment of disorders associated with a disturbed intestinal barrier integrity, such as for example irritable bowel syndrome. Further, a compound or composition comprising a microbial carotenoid compound is disclosed for use in the prevention and/or treatment of disorders associated with disturbed intestinal barrier integrity.

Abstract: The present invention provides stable pharmaceutical compositions, comprising a pharmaceutically effective amount of testosterone or a pharmaceutically acceptable ester thereof, a pharmaceutically acceptable oil vehicle, and a stabilizing amount of benzyl alcohol, for example, about 1% to 3% weight/volume of benzyl alcohol. The present invention also provides a process for stabilizing testosterone-containing pharmaceutical compositions by ageing them at a temperature of about 20° C. to about 60° C. for at least 48 hours, e.g., prior to secondary packing and labeling. These compositions were stable over the shelf life of the product, without exhibiting crystal formation, even upon storing at temperatures of about 2° C. to about 8° C. Other aspects of the invention relate to methods for making such pharmaceutical compositions, and methods of using such pharmaceutical compositions for hormone replacement therapy, e.g.

Abstract: The invention relates to treatment of graft versus host disease (GVHD) using compounds that inhibit ROCK2. In preferred aspects, the present invention provides methods for the treatment of GVHD, including chronic GVHD (cGVHD) using compounds having the formulae 1-XXV, as set forth herein.

Abstract: The present application provides methods of treating hidradenitis suppurativa in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound which inhibits JAK1 and/or JAK2, or a pharmaceutically acceptable salt thereof.

Abstract: Provided herein are pharmaceutical formulations comprising a monoacylglycerol lipase (MAGL) inhibitor, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient.

Abstract: The present disclosure provides compositions comprising ephedrine sulfate ready for immediate use in a clinical setting, and methods of making and using same.

Abstract: Methods for the treatment of cancer, including glioblastoma multiforme (GBM) and recurrent glioblastoma multiforme (RGBM). The method includes administering to a patient a plurality of extraneous antineoplastons and a plurality of targeted agents. The plurality of extraneous antineoplastons may include two or more antineoplastons selected from phenylacetylglutaminate sodium (PG), phenylacetylisoglutaminate sodium (iso-PG), and phenylacetate (PN). The plurality of targeted agents may include two or more agents selected from bevacizumab, pazopanib, sorafenib, dasatinib, and everolimus.

Abstract: The present invention provides a solid pharmaceutical formulation of PARP inhibitors and its use thereof, and more specifically a solid dispersion powder including 5-fluoro-1-(4-fluoro-3-(4-(pyrimidin-2-yl)piperazine-1-carbonyl)benzyl)quinazoline-2,4(1H,3H)-dione and polymers, wherein the content of polymers is from about 50 wt % to about 80 wt %, and wherein less than 10 wt % of 5-fluoro-1-(4-fluoro-3-(4-(pyrimidin-2-yl)piperazine-1-carbonyl)benzyl)quinazoline-2,4(1H,3H)-dione is in crystalline form. The present invention also provides a method for preparing the solid dispersion powder, a pharmaceutical composition including the solid dispersion powder and the use of the pharmaceutical composition for treating diseases caused by PARP activity abnormalities.